Table 1.
Patient characteristics
| Characteristic | No. (%) |
|---|---|
| All | 302 (100) |
| Patient status | |
| Age, yr | |
| < 70 | 209 (69.2) |
| ≥ 70 | 93 (30.8) |
| Sex | |
| Male | 189 (62.6) |
| Female | 113 (37.4) |
| Performance | |
| ECOG 0–1 | 278 (92.1) |
| ECOG 2–3 | 24 (7.9) |
| DM | |
| No | 175 (57.9) |
| Yes | 127 (42.1) |
| Tumor status | |
| Disease statusa,b | |
| Locally advanced | 41 (13.6) |
| Metastatic | 261 (86.4) |
| Primary cancer | |
| Head | 164 (54.3) |
| Body | 44 (14.6) |
| Tail | 71 (23.5) |
| Head and body | 2 (0.7) |
| Body and tail | 21 (7) |
| No. of metastatic lesions | |
| 0–2 | 97 (32.1) |
| > 2 | 205 (67.9) |
| 2nd line chemo | |
| Yes | 116 (38.4) |
| No or unknown | 186 (61.6) |
| Biomarkers | |
| WBC, /μLa | |
| < 10,000 | 250 (82.8) |
| ≥ 10,000 | 52 (17.2) |
| NLRa | |
| < 3.8 | 192 (63.6) |
| ≥ 3.8 | 110 (36.4) |
| PLRa | |
| < 180 | 184 (60.9) |
| ≥ 180 | 118 (39.1) |
| CRP, mg/La | |
| < 10.5 | 143 (47.3) |
| ≥ 10.5 | 159 (52.7) |
| CRP-albumin ratioa | |
| < 3.85 | 161 (53.3) |
| ≥ 3.85 | 141 (46.7) |
| Na, mmol/La | |
| <135 | 46 (15.2) |
| ≥135 | 256 (84.8) |
| Albumin, g/dLa | |
| < 3.5 | 61 (20.2) |
| ≥ 3.5 | 241 (79.8) |
| PLT, /μLa | |
| < 350,000 | 263 (87.1) |
| ≥ 350,000 | 39 (12.9) |
| CA 19-9, U/mLa | |
| < 1,000 | 183 (60.6) |
| ≥ 1,000 | 119 (39.4) |
ECOG, Eastern Cooperative Oncology Group; DM, diabetes mellitus; WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein; Na, sodium; PLT, platelet; CA 19-9, carbohydrate antigen 19-9.
a
At the start of chemotherapy.
b
Included recurred locally advanced/recurred metastatic.